Navigation Links
Octopus 301

ProductsOctopus 301
Company Interzeag AG
Item Octopus 301
Features 100% eye fixation control if fixation is lost, no stimulus is presented. Diagnostic programs with test stages prioritizing the most crucial field areas. Fast software for significantly shorter examinations avoid errors caused by patient and retinal fatigue. Continuous measurement of the pupil size allowing accurate assessment and comparison of data. The ergonomic design maximizes patient comfort. Cold light sources avoid heat dissipation and eliminate the noise of cooling fans. Electronic eye fixation adjustment without disturbing the patient. Simple operation on a color input screen guided by a dialog in any language. The clear Seven-in-One print-out presents the most complete information needed for the assessment of the results.
Description Designed around the patented Interzeag direct projection system the Octopus 301 sets the trend in perimetry for the next decade. Ideal for routine screening and threshold examinations, the proven performance, accuracy and quality of the 301 will benefit any office or clinic.
Info Interzeag AG
Customer Service: (41)-31-978 01 11
Web site: http://www.octopus.ch

Related medicine products :

1. Octopus 311
2. Octopus 101
3. Octopus 4 Tissue Stabilizer
4. Octopus3 Tissue Stabilizer (malleable pods)
5. Octopus4.3 Tissue Stabilizer
Toothed Pituitary IVD Rongeurs, 8 length 200 mm....
Ferris Smith Rongeurs, 12 overall length 300 mm....
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse....
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse....
Medicine Products:
(Date:11/27/2014)... "As a nurse I see patients ... urinary incontinence," said an inventor from Whiting, N.J. "I ... accessory to prevent leakage and keep them dry and ... leakage. This prevents stains on pants, skirts and bottoms, ... ensures that the individual has time to get to ...
(Date:11/27/2014)... 26, 2014 (HealthDay News) -- Most babies and young ... the U.S. Food and Drug Administration says. Over-the-counter ... to children younger than 2 because they could cause ... American adults average about three colds a year, ... a cold, parents might want to give them pain ...
(Date:11/27/2014)... 27, 2014 In order to enable people ... Fla., designed an easy way to avoid touching a toilet ... then created a prototype of the patent-pending Toilet Tamer, a ... toilet seat and/or lid in a more sanitary manner. It ... of germs. Overall, it promotes good hygiene and peace of ...
(Date:11/27/2014)... 2014 Now that Thanksgiving is finally ... launched, Emassagechair.com has announced its eagerly awaited, ... , Negotiating on behalf of their customers, and ... brands, Emassagechair.com has generated significant buzz in the industry ... discounts yet. , Shoppers are excited for significant savings ...
(Date:11/27/2014)... VogueQueen.com is making every effort to ... the world. As the premier online supplier of elegant ... to release a huge selection of sexy prom dresses ... is also providing many beautiful styles in its product ... at discounted prices. , “VogueQueen.com hopes to provide a ...
Breaking Medicine News(10 mins):Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:A New Collection of Sexy Prom Dresses Has Been Released by the Reliable Online Supplier VogueQueen.com 2
... A new link between obesity and type 2 diabetes found ... drug treatments for diabetes, University of Michigan Health System research ... insulin, which lowers blood glucose levels. But the U-M study ... opposite effect of insulin by raising blood glucose levels ...
... the non-FDA-approved use of antipsychotic drugs may be a way ... according to a Penn State College of Medicine study. ... medications in data from 2003 did not have schizophrenia or ... for use. Use of medication for treatments that is not ...
... that the strongest risk factors for atrial fibrillation in both ... While hypertension is a well known risk factor for AF, ... later occurrence of AF has not been documented earlier". ... and is a major risk factor for heart failure (risk ...
... a common chemotherapy drug before bone tumors took root ... introduced, to seed and grow more easily. ... cancers metastasize to bone, and could eventually result in ... Department of Periodontics and Oral Medicine at the ...
... May 14 (HealthDay News) -- People with HIV/AIDS are four ... those in the general population, a new study finds. ... according to researchers from the University of California, San Francisco ... cardiac death, the heart suddenly and unexpectedly stops beating. ...
... A new study that looked at the hunger trends ... in the United States, more than one in seven, face ... "In 2005, we reported that one in nine seniors ... Illinois associate professor of agricultural and consumer economics and executive ...
Cached Medicine News:Health News:New inflammation hormone link may pave way to study new drugs for Type 2 diabetes 2Health News:Reducing off-label use of antipsychotic medications may save money 2Health News:Reducing off-label use of antipsychotic medications may save money 3Health News:Palpitations are predictive of future atrial fibrillation 2Health News:Palpitations are predictive of future atrial fibrillation 3Health News:'Fertilizing' bone marrow helps answer why some cancers spread to bones 2Health News:People With HIV at Higher Odds of Sudden Cardiac Death 2Health News:Great recession reflux amounts to more hunger among seniors 2
(Date:11/26/2014)... , November 25, 2014 ... Instruments Market by Power Source (Electric, Battery, Pneumatic), ... Cables, Blade, Burr, Cart), by Application (Orthopedic, ENT, ... published by MarketsandMarkets, the global Powered Surgical Instruments Market ... $1.6 Billion in 2014 and is expected to ...
(Date:11/26/2014)... , Nov. 25, 2014 ... focused on the development of mobile diagnostic ... testing in hospital and pre-hospital settings, today ... (ISO) 13485:2003 certification.  The certification was awarded ... of the world,s leading certification bodies. ...
(Date:11/26/2014)... LONDON , Nov. 25, 2014 Amgen ... AZN ) today announced that AMAGINE-2 TM , a pivotal, ... more than 1,800 patients with moderate-to-severe plaque psoriasis, met its ... and placebo at week 12. Brodalumab 210 mg given every ... shown to be superior to Stelara on the primary endpoint ...
Breaking Medicine Technology:Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4Nanomix Receives ISO 13485:2003 Certification 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10